Sanaria
Sanaria

Mission Statement

Sanaria's primary mission is to develop and commercialize whole-parasite sporozoite vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the malaria parasite responsible for more than 95% of malaria associated severe illness and death world-wide and the malaria parasite for which there is the most significant drug resistance.

Foundation for Mission Statement

Annually, malaria caused by Plasmodium falciparum causes greater than 300 million clinical cases and one million deaths, is responsible for loss of greater than 1% of Gross Domestic Product in Africa, and is a serious concern for travelers and military personnel. An effective vaccine could have a dramatic impact on the disease. For 20 years scientists have tried to develop modern, recombinant "sub-unit" malaria vaccines. This has been difficult. In fact there are only two recombinant protein vaccines on the market for any disease, and no vaccines based on synthetic peptides, recombinant viruses, recombinant bacteria, or DNA plasmids. Most vaccines are based on attenuated or inactivated whole pathogens or material derived directly from the infectious agent. It is in that context that the report (see PDF in publications section) summarizing the protection of humans with metabolically active, non-replicating (=attenuated or weakened) Plasmodium falciparum sporozoites produced at 4 different sites over 25 years is important. In studies utilizing live mosquitoes as the vaccine delivery mechanism, there was complete protection against malaria in 93% of volunteers (13/14) and 94% of challenges (33/35). Protection was shown to last for at least 10 months, and to be effective against multiple different strains of Plasmodium falciparum. This level of protection is as good, or better, than the protection afforded by any vaccine for any disease on the world’s markets, and far better than the protection afforded by any experimental malaria vaccine under development.

Thus, our starting point is with an immunogen that has already been shown to be effective, not a technology or platform that has the "potential" to be effective.

 

disclaimer     site map

copyright(c) 2003-2014, Sanaria Inc., all rights reserved
website design by cymaxmedia.com